header logo image


Page 17«..10..15161718

Archive for the ‘Nano medicine’ Category

Nanomedicine Fact Sheet – Genome.gov | National Human …

Thursday, August 4th, 2016

Nanomedicine Overview

What if doctors had tiny tools that could search out and destroy the very first cancer cells of a tumor developing in the body? What if a cell's broken part could be removed and replaced with a functioning miniature biological machine? Or what if molecule-sized pumps could be implanted in sick people to deliver life-saving medicines precisely where they are needed? These scenarios may sound unbelievable, but they are the ultimate goals of nanomedicine, a cutting-edge area of biomedical research that seeks to use nanotechnology tools to improve human health.

Top of page

A lot of things are small in today's high-tech world of biomedical tools and therapies. But when it comes to nanomedicine, researchers are talking very, very small. A nanometer is one-billionth of a meter, too small even to be seen with a conventional lab microscope.

Top of page

Nanotechnology is the broad scientific field that encompasses nanomedicine. It involves the creation and use of materials and devices at the level of molecules and atoms, which are the parts of matter that combine to make molecules. Non-medical applications of nanotechnology now under development include tiny semiconductor chips made out of strings of single molecules and miniature computers made out of DNA, the material of our genes. Federally supported research in this area, conducted under the rubric of the National Nanotechnology Initiative, is ongoing with coordinated support from several agencies.

Top of page

For hundreds of years, microscopes have offered scientists a window inside cells. Researchers have used ever more powerful visualization tools to extensively categorize the parts and sub-parts of cells in vivid detail. Yet, what scientists have not been able to do is to exhaustively inventory cells, cell parts, and molecules within cell parts to answer questions such as, "How many?" "How big?" and "How fast?" Obtaining thorough, reliable measures of quantity is the vital first step of nanomedicine.

As part of the National Institutes of Health (NIH) Common Fund [nihroadmap.nih.gov], the NIH [nih.gov] has established a handful of nanomedicine centers. These centers are staffed by a highly interdisciplinary scientific crew, including biologists, physicians, mathematicians, engineers and computer scientists. Research conducted over the first few years was spent gathering extensive information about how molecular machines are built.

Once researchers had catalogued the interactions between and within molecules, they turned toward using that information to manipulate those molecular machines to treat specific diseases. For example, one center is trying to return at least limited vision to people who have lost their sight. Others are trying to develop treatments for severe neurological disorders, cancer, and a serious blood disorder.

The availability of innovative, body-friendly nanotools that depend on precise knowledge of how the body's molecular machines work, will help scientists figure out how to build synthetic biological and biochemical devices that can help the cells in our bodies work the way they were meant to, returning the body to a healthier state.

Top of page

Last Updated: January 22, 2014

Original post:
Nanomedicine Fact Sheet - Genome.gov | National Human ...

Read More...

Nanomedicine Conferences| Nanotechnology conferences| 2016 …

Thursday, August 4th, 2016

Conference Series LLCinvites all the participants from all over the world to attend 10th International Conference on Nanomedicine and Nanotechnology in Health Care during July 25-27, 2016 at Avani Atrium, Bangkok, Thailand. It will include presentations and discussions to help attendees address the current trends and research on the applications of Nanomedicine and nanotechnology in healthcare. The theme of the conference is "Embarking Next Generation Delivery Vehicles for affordable Healthcare!"

Nanomedicineis innovating the healthcare industry and impacting our society, but is still in its infancy in clinical performance and applications. The aim of thisNanomedicine 2016conference is to bring together leading academic, clinical and industrial experts to discuss development of innovative cutting-edge Nanomedicine and challenges in Nanomedicine clinical translation.

Track 01:Nanomedicine

Nanomedicine applications in the field of medicine are vast. It helps in the detection, diagnosis, prevention, treatment and follow-up of many diseases.Personalized Nanomedicineis being applied in all the branches of medicine like Radiology, Neurology, Surgery, Pulmonology, Dentistry, Orthopaedics, Ophthalmology etc.Nanomedicine conferencesfocusses on how Nanomedicine can be the next delivery vehicle for making healthcare affordable.

RelatedNanomedicine Conferences|Nano science Meeting |Healthcare Meeting

Nanomaterials Conference April 21-23 2016, UAE; MedicalNanotechnologySummit June 9-11 2016, Dallas; Molecular Nanoscience Meeting September 26-28 2016, UK; Nanotechnology Expo November 10-12 2016, Australia; Nanotech Expo December 5-7 2016, USA; International Conference onNanoscienceand Nanotechnology (ICONN), 711 February 2016, Australia; International Conference onNanobiotechnology, Drug Delivery, and Tissue Engineering, 1st- 2ndApril 2016, Czech Republic; International Conference on Biotechnology, Bioengineering andNanoengineering, April 14-15, 2016, Portugal; Meeting and Expo onNanomaterialsand Nanotechnology, 25th - 27th April 2016, UAE;NANOTEXNOLOGY, 29 July, 2016, Greece, American Society For Nanomedicine, Washington, USA, Society for Personalized Nanomedicine, Florida, USA

Track 02: Nanomedicine and Drug delivery

There are a many ways thatnanotechnologycan make the delivery of drugs more systematic and accost effective treatment for the patient. Numerous biological materials like albumin, gelatine and phospholipids for liposomes, and more substances of a chemical nature like various polymers and solid metal containing nanoparticles are under investigation for preparation of nanoparticles. The hazards that are introduced by usingnanoparticles for drug deliveryare more than that posed by conventional hazards imposed by chemical delivery.

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

Bioavailability and Bioequivalence Summit August 29-31, 2016, USA;Surgical OncologyConference during September 01-03, 2016, Brazil; Precision Medicine ConferenceNovember 03-05, 2016, USA; Translational MedicineConference November 17-19, 2016, USA;Mesothelioma Summit,November 03-04, 2016, Spain; International Conference onBiotechnologyand Nanotechnology, April 14-15, 2016, Portugal;Nanotech Conference & Exhibition, 01-03 June, 2016, France; Materials Scienceand Nanotechnology Conference July 28- 29, 2016, China; 7thInternationalnanotechnology Summit: fundamentals and applications, August 19-10, 2016 Hungary, Society for Personalized Nanomedicine, Florida, USA, European Society for Nanomedicine, Basel, Switzerland

Track 03:Nanomedicine and Nanotechnology

Nanomedicine is an emerging specialty born from Nanotechnology. Bothnanomedicine and nanotechnologyare emerging as the new direction in the diagnosis and drug therapy. Nanomedicine can change the face of healthcare in the future using nanotechnology.Nanomedicinehelps detect, repair, understand and control the human biological system. Nanomedicine can be used forpersonalized Nanomedicine.

RelatedNanomedicine Conferences|Nano science Meeting |Healthcare Meeting:

Nanomaterials Conference April 21-23 2016, UAE; MedicalNanotechnologySummit June 9-11 2016, Dallas; Molecular Nanoscience Meeting September 26-28 2016, UK; Nanotechnology Expo November 10-12 2016, Australia; Nanotech Expo December 5-7 2016, USA; International Conference onNanoscienceand Nanotechnology (ICONN), 711 February 2016, Australia; International Conference onNanobiotechnology, Drug Delivery, and Tissue Engineering, 1st- 2ndApril 2016, Czech Republic, Biotechnology, Bioengineering andNanoengineering Conference, April 14-15, 2016, Portugal; Nanomaterials Conferenceand Nanotechnology, 25th - 27th April 2016, UAE;NANOTEXNOLOGY, 29 July, 2016, Greece, International Association of Nanotechnology, California, USA, French Society for Nanomedicine, Lille, France

Track 04:Nanomedicine and Nanobiotechnology

Nanobiotechnologyis the intersection of nanotechnology and biology. Nanobiotechnology has multitude of potentials for advancing medical science thereby improving health care practices around the world. Nanomedicine is used to treat diseases bygene therapy. Nano biotechnologies are being applied to molecular diagnostics and several technologies are in development.

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

NanoConference June 20-21, 2016 Cape Town, South Africa; Medical NanotechnologyCongress and Expo June 9-11, 2016 Dallas, USA; Nanotechnology Congress June 27-29, 2016 Valencia, Spain; 11th Nanobiotechnology MeetingSeptember 26-28, 2016 London, UK: Nanotechnology Expo November 10-12, 2016 Melbourne, Australia: International Conference on NanotechnologyModellingand Simulation April 1-2, 2016 Prague, Czech Republic: The 5th Conference onNanomaterialsJanuary 14-16, 2016 Bangkok, Thailand: Nanotechnology Conference and Expo Baltimore, USA, 4th to 6th April 2016: 4thNanoscience Conference (ICNT2016) Kuala Lumpur, Malaysia, 28th - 29th January 2016: 4th Conference on Materials ScienceNew York, USA, American Nano Society, Florida, USA, Sustainable Nanotechnology Organization, Washington, USA

Track 05:Nanomedicine and Bioengineering

Nanomedicinehas a considerable role in Bioengineering. To design and construct an apt scaffold is the major challenge inRegenerative medicinetoday. The cell-cell and cell-matrix interactions in the biosystems happen at the nanoscale level. Therefore the application of nanotechnology at that level helps in modifying the cellular function to mimic the native tissue in a more appropriate way. The application ofBioengineeringhas transformed the designing the manufacturing of scaffolds and artificial grafts.

RelatedNanomedicine Conferences|Nano science Meeting |Healthcare Meeting:

Stem Cell Research conference February 29-March 02 2016, USA, Bio banking ConferenceAugust 18-19 2016, USA; Regenerative Medicine Conference,September 12-14 2016, Germany; 6th Pharmacogenomics ConferenceSeptember 12-14, 2016, Berlin, Germany; Conference onRestorative MedicineOctober 24-26, 2016, USA ; Conference onRegeneration, January 10 14, 2016, USA; ISSCR Conference onNeural Degenerationand Disease, 18th Biotechnology Meeting, April 11-12, 2016, Italy; 14th European Symposium on Drug Delivery, 13th-15thApril 2016, The Netherlands Sustainable Nanotechnology Organization, Washington, USA, Asian Nanoscience and Nanotechnology Association, Kagawa, Japan

Track 06:Nanomedicine and Cancer

Cancer Nanomedicineaims to use the nanostructures and nanoscale processes for the prevention, detection, diagnosis and treatment of cancer and other concomitant areas. Even when molecular changes occur in a smaller percentage of cells, which may be cancer related targets.Nanomedicine in cancercan help in the sensitive detection of them. The use of Nanotechnology to combat cancer is still under development. Severalnanocarrierdrugs andnanotherapeuticsare available in market and some in Clinical trials.

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

CancerDiagnostics Expo June 13-15 2016, Italy; Conference onCancer Immunologyand Immunotherapy July 28-30 2016, Australia;Cancer GenomicsSummit August 8-9 2016, USA; 12th Cancer TherapySummit September 26-28 2016, UK; International Conference onCervical CancerSeptember 22-23 2016, Austria; TheBiomarkerConference, 18th-19th February 2016, USA; Cancer Vaccines: Targeting Cancer Genes forImmunotherapy, March 610 2016, Canada; 18th Conference on Biotechnology Advances, April 11-12, 2016, Italy; 14th European Drug Delivery Summit, April 13-15 2016, The Netherlands; 18th InternationalCancer NanomedicineConference and Novel Drug Delivery Systems, April 22 - 23, 2016, United Kingdom, Asian Nanoscience and Nanotechnology Association, Kagawa, Japan, European Nanoscience and Nanotechnology Association, Bulgaria.

Track 07:Nanomedicine and Healthcare

Nanomedicineaffects almost all the aspects of healthcare. Nanomedicine helps to engineer novel and advanced tools for the treatment of various diseases and the improvement of human biosystems usingmolecular Nanotechnology. Cardiovascular diseases, Neurodegenerative disorders, Cancer, Diabetes, Infectious diseases, HIV/AIDS are the main diseases whose treatment can be benefitted by using nanomedicine.

RelatedNanomedicine Conferences|Nano science Meeting |Healthcare Meeting:

Bioequivalence and Bioavailability Summit August 29-31, 2016, USA;Surgical OncologyConference during September 01-03, 2016, Brazil; Precision Medicine ConferenceNovember 03-05, 2016, USA; Translational MedicineConference November 17-19, 2016, USA;Mesothelioma Summit,November 03-04, 2016, Spain; International Conference onBiotechnologyand Nanotechnology, April 14-15, 2016, Portugal;Nanotech Conference & Exhibition, 01-03 June, 2016, France; Materials Scienceand Nanotechnology Conference July 28- 29, 2016, China; 7thInternationalnanotechnology Summit: fundamentals and applications, August 19-10, 2016 Hungary, Society for Personalized Nanomedicine, Florida, USA, European Society for Nanomedicine, Basel, Switzerland

Track 08:Nanomedicine and Healthcare Applications

Nanomedicineapplications in healthcare Industry are broad. It helps to engineer newNano medical devices, design nanoparticles for detection and drug delivery in cancer. Nanomedicine can be applied in allied areas of healthcare like Wound healing, Food Industry and Hair growth. Nanomedicine is being widely used forpublic health and Nutrition.

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

NanoConference June 20-21, 2016 Cape Town, South Africa; Medical NanotechnologyCongress and Expo June 9-11, 2016 Dallas, USA; Nanotechnology Congress June 27-29, 2016 Valencia, Spain; 11th Nanobiotechnology MeetingSeptember 26-28, 2016 London, UK: Nanotechnology Expo November 10-12, 2016 Melbourne, Australia; International Conference on NanotechnologyModellingand Simulation April 1-2, 2016 Prague, Czech Republic: The 5th Conference onNanomaterialsJanuary 14-16, 2016 Bangkok, Thailand: Nanotechnology Conference and Expo Baltimore, USA, 4th to 6th April 2016: 4thNanoscience Conference (ICNT2016) Kuala Lumpur, Malaysia, 28th - 29th January 2016: 4th Conference on Materials ScienceNew York, USA, American Nano Society, Florida, USA, Sustainable Nanotechnology Organization, Washington, USA.

Track 09: Nanotechnology and Food

Nanotechnology has begun to find potential applications in the area of functional food by engineering biological molecules toward functions very different from those they have in nature, opening up a whole new area of research and development. Of course, there seems to be no limit to whatfood technologistsare prepared to do to our food and nanotechnology will give them a whole new set of tools to go to new extremes. Nanotechnology may revolutionize the food industry by providing stronger, high-barrier packaging materials, more potent antimicrobial agents, and a host of sensors which can detect trace contaminants, gasses or microbes in packaged foods.

RelatedNanomedicine Conferences|Nano science Meeting |Healthcare Meeting:

Biopolymers Congress, August 01-03, 2016, UK; Conference onSustainable BioplasticsNovember 10-12, 2016, Spain; Biopolymers andBioplastics Summit, September 12-14, 2016, USA; Biofuelsand Bioenergy September 1-3, 2016, Brazil; Public HealthSummit March 10-12, 2016, Spain; 5th Annual PharmaceuticalMicrobiology Conference, 2021 January 2016, United Kingdom; 18th International Conference on Biomaterials,Colloidsand Nanomedicine, January 21-22, 2016, France; 13th National Conference and Technology Exhibition On Medical Devices &PlasticsDisposables, February 12-13, 2016, USA; 18th International Conference onToxicology, February 25 - 26, 2016; United Kingdom; Faraday Discussion:Nanoparticleswith Morphological and Functional Anisotropy, 46 July 2016, United Kingdom, Asian Nanoscience and Nanotechnology Association, Kagawa, Japan, European Nanoscience and Nanotechnology Association, Bulgaria

Track 10:Nanomedicine and Nanotheranostics

Nanotheranosticscombine both the Non-invasive diagnosis and treatment of diseases and helps to monitor the drug release and dispersion of the drug, thereby increasing the effectiveness of therapy.Cancer nanotheranosticshold a great promise in improving the treatment outcomes in Cancer. Nanotheranostics are currently being used in theBiomarker Discovery. Nanotheranostics include both Genomics based theranostics and Proteomics based theranostics

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

Pharmacology SummitAugust 08-10 2016, UK;Conference onClinical TrialsAugust 22-24 2016, USA; Neuropharmacology MeetingSeptember 15-17 2016, USA;PharmacovigilanceSummit September 19-21 2016 in Austria; Drug DiscoveryExpo October 24-26 2016, Turkey; 18th International Conference onBioengineering, Biotechnology and Nanotechnology, January 18 - 19, 2016, United Kingdom; 4thImmunogenicity& Immunotoxicity Conference January 25-26, 2016, USA; Genomics andpersonalized medicine conference, 07-11 February, 2016, Canada;Conference onAntibodiesas Drugs, 06-10 March, 2016, Canada; Pharmaceutical Sciences Congress, 28 August - 1 September 2016, Argentina, American Society For Nanomedicine , Washington, USA, Society for Personalized Nanomedicine, Florida, USA

Track 11: Nanomedicine and Nanobiology

Nano biologyis the branch where basic biology of the organism and nanotechnology meet. Nano biology helps in addressing the basic mechanisms of human health and diseases at the cellular and molecular level.Nano biologyapplied in microbiology is Nanomicrobiology. Recently certain nanoparticles are being designed to act against infections

RelatedNanomedicine Conferences|Nano science Meeting |Healthcare Meeting:

Conference onPharmaceutics March 07-09 2016, Spain; BiosimilarsCongress June 27-29, 2016 Valencia, Spain; Drug DeliverySummit June 30- July 02 2016, USA; Conference onPharmaceuticalRegulatory Affairs and IPR September 12-14 2016, USA; Asia Pacific MassSpectrometryCongress October 10-12 2016, Malaysia;Advanced MaterialsConference (IC2NAM), January 15th 2016; New Zealand; Modern PhenotypicDrug Discovery Summit: Defining the Path Forward, April 26, 2016; USA; 10th IEEE international Conference on Molecular Medicineand Engineering, 17-20 April 2016, Japan; 2ndDrug Delivery Meeting: Advanced Mechanisms & Product Design, May 18-19, 2016, 2016; 6th International Conference on Manipulation, Manufacturing and Measurement on theNanoscale, 18-22 July 2016, China, International Association of Nanotechnology, California, USA, French Society for Nanomedicine, Lille, France, , Asian Nanoscience and Nanotechnology Association, Kagawa, Japan, European Nanoscience and Nanotechnology Association, Bulgaria

Track 12:Nanomedicine and Nanopharmaceuticals

Nanopharmaceuticalssuch as liposomes,quantum dots, dendrimers,carbon nanotubesand polymeric nanoparticles have brought considerable changes in drug delivery and the medical system. Nanopharmaceuticals offer a great benefit for the patients in comparison with the conventional drugs. There are several advantages of these drugs such as enhanced oral bioavailability, improved dose proportionality, enhanced solubility and dissolution rate, suitability for administration and reduced food effects.

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

Conference onPharmaceutics March 07-09 2016, Spain; BiosimilarsCongress June 27-29, 2016 Valencia, Spain; Drug DeliverySummit June 30- July 02 2016, USA; Conference onRegulatory Affairs and IPR September 12-14 2016, USA; Asia Pacific MassSpectrometryCongress October 10-12 2016, Malaysia;Advanced MaterialsConference (IC2NAM), January 15th 2016; New Zealand; Modern PhenotypicDrug Discovery: Defining the Path Forward, April 26, 2016; USA; 10th IEEE international Conference on Molecular Medicineand Engineering, 17-20 April 2016, Japan; 2ndDrug Delivery Meeting: Advanced Mechanisms & Product Design, May 18-19, 2016, 2016; 6th International Conference on Manipulation, Manufacturing and Measurement on theNanoscale, 18-22 July 2016, China, International Association of Nanotechnology, California, USA, French Society for Nanomedicine, Lille, France.

Track 13:Nanomedicine and Nanotoxicology

Nanotoxicologyis intended to address the toxicological activities of nanoparticles and their products to determine whether and what extent they may pose a threat to the environment and to human health and defined as the study of the nature and mechanism of toxic effects of nanoscale materials/particles on living organisms and other biological systems. It also deals with the quantitative assessment of the severity and frequency of nanotoxic effects in relation to the exposure of the organisms. The knowledge from nanotoxicology study will be the base for designing safenanomaterialsandnanoproducts,and also direct used innanomedicalsciences.

RelatedNanomedicine Conferences|Nano science Meeting |Healthcare Meeting:

Pharmacology andEthnopharmacology Conference May 02-04 2016, USA; Conference on Toxicogenomics June 09-10 2016, USA; Environmental ToxicologySummit August 25-26 2016, Brazil; BiosimilarsCongress September 12-14, 2016 USA; ToxicologySummit October 27-29 2016, Italy;Biosimilarsand Biologics Congress 1-2 February, 2016, Germany; The Oxford ChemicalImmunologyConference, 45 April 2016, United Kingdom; Toxicology and risk assessment conference, April 4-6, 2016; USA; 18th International Conference onBioinformaticsand Bioengineering, April 25-16, 2016, France; Toxicology Meeting, September 47, 2016, Turkey, Society for Personalized Nanomedicine, Florida, USA, European Society for Nanomedicine, Basel, Switzerland

Track 14:Nanomedicine and Nanomedical Devices

Nanomedical devicesshow great promise in various applications for health care. Many nano scale devices have already been approved by the FDA. Nano scale materials can be used as delivery mechanisms allowing cells to absorb therapeutics into the cell wall. Various nano materials are being researched for use in cancer therapeutics.Nanowiresand needles are being researched and developed for use in epilepsy and heart control.Nanosized surgical instrumentscan be used to perform microsurgeriesand better visualization of surgery.

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

Generic Drug Market Expo Oct 31- Nov 02 2016, Spain; Medical Devices Expo December 1-3 2016, USA; African Surgical and Medical Devices Expo June 20-21, 2016, South Africa; Conference on Biomaterials March 14-16 2016, UK; Bioavailability & Bioequivalence Summit August 29-31 2016, USA; Microbiology Summit, 2021 January 2016, United Kingdom; 18th International Conference on Biomaterials, Colloids and Nanomedicine, January 21-22, 2016, France; 13th Medical Devices Exhibition & Plastics Disposables, February 12-13, 2016, USA; 18th International Conference on Toxicology, February 25 - 26, 2016; United Kingdom; Faraday Discussion: Nanoparticles with Morphological and Functional Anisotropy, 46 July 2016, United Kingdom, International Association of Nanotechnology, California, USA, French Society for Nanomedicine, Lille, France

Track 15:Nanomedicine and Nanodiagnostics

The use of Nanotechnology in clinical diagnosis is termed asNano diagnostics. Diagnosis at the single cell level or molecular level can be possible through Nano diagnostics. They can even be incorporated even in the current diagnostic methods like Biochips.Nanobiosensorsare promising devices for Clinical applications.

RelatedNanomedicine Conferences|Nano science Meeting |Healthcare Meeting:

Bioavailability and Bioequivalence Summit August 29-31, 2016, USA;Surgical OncologyConference during September 01-03, 2016, Brazil; Precision Medicine ConferenceNovember 03-05, 2016, USA; Translational MedicineConference November 17-19, 2016, USA;Mesothelioma Summit,November 03-04, 2016, Spain; International Conference onBiotechnologyand Nanotechnology, April 14-15, 2016, Portugal;Nanotech Conference & Exhibition, 01-03 June, 2016, France; Materials Scienceand Nanotechnology Conference July 28- 29, 2016, China; 7thInternationalnanotechnology Summit: fundamentals and applications, August 19-10, 2016 Hungary, Society for Personalized Nanomedicine, Florida, USA, European Society for Nanomedicine, Basel, Switzerland.

Track 15:Nanoethics and Regulations

Nanoethicsis the study ethical and social implications of nanotechnologys. It is an emerging but controversial field.Nanoethics is a debatable field.As the research is increasing on nanomedicine, there are certain regulations to increase their efficacy and address the associated safety issues. Other issues in nanoethics include areas likeresearch ethics, environment,global equity, economics, politics, national security, education, life extension and space exploration.

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

Generic Drug Market Expo Oct 31- Nov 02 2016, Spain; Medical Devices Expo December 1-3 2016, USA; African Surgical and Medical Devices Expo June 20-21, 2016, South Africa; Conference on Biomaterials March 14-16 2016, UK; Bioavailability & Bioequivalence Summit August 29-31 2016, USA; Microbiology Summit, 2021 January 2016, United Kingdom; 18th International Conference on Biomaterials, Colloids and Nanomedicine, January 21-22, 2016, France; 13th Medical Devices Exhibition & Plastics Disposables, February 12-13, 2016, USA; 18th International Conference on Toxicology, February 25 - 26, 2016; United Kingdom; Faraday Discussion: Nanoparticles with Morphological and Functional Anisotropy, 46 July 2016, United Kingdom, International Association of Nanotechnology, California, USA, French Society for Nanomedicine, Lille, France.

Track 17:Nanomedicine Technologies

Nanomedicine technologiescould find an enhanced position in various areas and applications of the healthcare sector including drug delivery, drug discovery, screening and development, diagnostics and medical devices.BIOMEMSrefers to the application of micro electromechanical systems to micro- and nanosystems for genomics, proteomics, drug-delivery analysis, molecular assembly, tissue engineering, biosensor development, nanoscale imaging, etc.Nanoroboticsrefers to the still largely theoretical nanotechnology engineering discipline of designing and building nanorobots. Different companies are developing novel technologies in Nanomedicine likeNanoTherm therapyandNanobody technology. Nanomedicine in drug discovery is playing a key role in the growing part of pharmaceutical research and development.

RelatedNanomedicine Conferences|Nanotechnology Conferences|Healthcare Meeting:

Pharmacology andEthnopharmacology Conference May 02-04 2016, USA; Conference on Toxicogenomics June 09-10 2016, USA; Environmental ToxicologySummit August 25-26 2016, Brazil; BiosimilarsCongress September 12-14, 2016 USA; ToxicologySummit October 27-29 2016, Italy;Biosimilarsand Biologics Congress 1-2 February, 2016, Germany; The Oxford ChemicalImmunologyConference, 45 April 2016, United Kingdom; Toxicology and risk assessment conference, April 4-6, 2016; USA; 18th International Conference onBioinformaticsand Bioengineering, April 25-16, 2016, France; Toxicology Meeting, September 47, 2016, Turkey, Society for Personalized Nanomedicine, Florida, USA, European Society for Nanomedicine, Basel, Switzerland.

Conference Series LLCinvites the contributors across the globe to participate in the premier International Conference on Nanomedicine and Nanotechnology in Health Care (Nanomedicine-2016), to discuss the theme: "Nanomedicine: The Remarkable Technology Thats Changing the Face of Healthcare The conference will be held at Avani Atrium, Bangkok, Thailand during July 25-27,2016.

Conference Series Llc organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members

International Conference on Nanomedicine and Nanotechnology in Health Care (Nanomedicine 2016) aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Nanomedicine in Healthcare. It also provides the premier interdisciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the field of Nanomedicine. The conference program will cover a wide variety of topics relevant to the nanomedicine, including: nanomedicine in drug discover and delivery, nanodiagnostics, theranostics, applications of nanomedine in healthcare applications and disease treatments.

Why to attend?

With members from around the world focused on learning about nanomedicine and its advances; this is your best opportunity to reach the largest assemblage of participants from the Nanotechnology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 3-day event.

Target Audience:

Nanomedicine Academia Professors , Medical professionals, Nanomedicine Department heads, Nanomedicine researchers, Nanomedicine CTOs, Nanomedicine product managers, business development managers, Entrepreneurs, Industry analysts, Investors, Students, Media representatives and decision makers from all corners of Nanoscience research area around the globe.

We therefore encourage all colleagues from all over the world to participate and help us to make this an unforgettable important and enjoyable meeting.

We look forward to seeing you in Bangkok, Thailand !!!

For more

10th International conference on Nanomedince and Nantotechnology in Healthcare

July 25-27, 2016 Bangkok, Thailand

Summary of Nanomedicine Conference:

Nanomedicine 2016 welcomes attendees, presenters, and exhibitors from all over the world to Bangkok, Thailand. We are delighted to invite you all to attend and register for the 10th International conference and exhibition on Nanomedicine and Nanotechnology in Healthcare which is going to be held during July 25-27, 2016 at Bangkok, Thailand. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Nanomedicine-2016, where you will be sure to have a meaningful experience with scholars from around the world. All the members of Nanomedicine 2016 organizing committee look forward to meet in person.

Scope and Importance:

The emergence of nanomedicine and the application of nanomaterials in the healthcare industry will bring about groundbreaking improvements to the current therapeutic and diagnostic scenario. Some of the drivers of this market include increasing research funding, rising government support, improved regulatory framework, technological know-how and rising prevalence of chronic diseases such as diabetes, cancers, obesity, kidney disorders, orthopedic diseases and others.

Market Analysis:

In the past few years, the global nanomedicine market has witnessed an increasing use of novel nanomaterials and emergence of nanorobotics on a global front. The market has also observed a significant demand for personalized medicines due to its ability to treat patients based on customized treatments and other medical and genetic conditions.

Overall research in various disciplines:

The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia-Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region. In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases.

However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region. China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.

Nanomedicine study in various countries:

Companies involved in Nanomedicine:

GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories are some of the major companies in the Nanomedicine market.

Why Bangkok, Thailand?

Bangkok is the cultural, economic and political capital of Thailand. The city features both old-world charm and modern convenience. Many visitors in Bangkok are overwhelmed by the sheer size of the city and the vast number of attractions it has to offer. Indeed, there are many sightseeing opportunities in Bangkok, spanning for more than two centuries of rapid development following the citys founding in 1782. As Bangkok is considered a transport hub and a popular travel destination in Asia, we believe it would be beneficial to all the delegates who are attending the conference.

At present the research on nanomedicine is currently less due to the unavailability of funds and lack of proper expertise. The Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region. China is expected to surpass the United States.

Conference Highlights:

View original post here:
Nanomedicine Conferences| Nanotechnology conferences| 2016 ...

Read More...

NMI Table of Contents Page – Nanomedicine

Thursday, August 4th, 2016

Robert A. Freitas Jr., Nanomedicine, Volume I: Basic Capabilities, Landes Bioscience, Georgetown, TX, 1999; http://www.nanomedicine.com/NMI.htm

Nanomedicine, Vol. I: Basic Capabilities (Landes Bioscience, 1999). The first volume of the Nanomedicine book series describes the set of basic capabilities of molecular machine systems that may be required by many, if not most, medical nanorobotic devices, including the physical, chemical, thermodynamic, mechanical, and biological limits of such devices. Specific topics include the abilities to recognize, sort and transport important molecules; sense the environment; alter shape or surface texture; generate onboard energy to power effective robotic functions; communicate with doctors, patients, and other nanorobots; navigate throughout the human body; manipulate microscopic objects and move about inside a human body; and timekeep, perform computations, disable living cells and viruses, and operate at various pressures and temperatures.

Japanese language version of Nanomedicine, Vol. I, published in 2007 by Yakuji Nippo, Ltd:

1999 Robert A. Freitas Jr. All Rights Reserved.

Go here to read the rest:
NMI Table of Contents Page - Nanomedicine

Read More...

Nanorobots in Medicine – Nanomedicine

Wednesday, September 16th, 2015

Nanorobots in Medicine

Future applications of nanomedicine will be based on the ability to build nanorobots. In the future these nanorobots could actually be programmed to repair specific diseased cells, functioning in a similar way to antibodies in our natural healing processes.

Developing Nanorobots for Medicine

Design analysis for a cell repair nanorobot: The Ideal Gene Delivery Vector: Chromallocytes, Cell Repair Nanorobots for Chromosome Repair Therapy

Design analysis for an antimicrobial nanorobot: Microbivores: Artifical Mechanical Phagocytes using Digest and Discharge Protocol

A Mechanical Artificial Red Cell: Exploratory Design in Medical Nanotechnology

Nanorobots in Medicine: Future Applications

The elimination of bacterial infections in a patient within minutes, instead of using treatment with antibiotics over a period of weeks.

The ability to perform surgery at the cellular level, removing individual diseased cells and even repairing defective portions of individual cells.

Significant lengthening of the human lifespan by repairing cellular level conditions that cause the body to age.

Nanomedicine Reference Material

An online copy of volume one of the bookNanomedicine by Robert Freitas.

Chapter 7: "Engines of Healing" from the book Engines of Creation, The Coming Era of Nanotechnology by Eric Drexler

For a fun, fictionalized account of miniaturized medicine rent the 1966 movie Fantastic Voyage, or read the novelization of the movie by Isaac Asimov.

Institute of Robotics and Intelligent Systems

Nanomedicine Center for Nucleoprotein Machines

Related Pages

In about 20 years researchers plan to have the capability to build an object atom by atom or molecule by molecule. Molecular manufacturing, also called molecular nanotechnology will provide the ability to build the nanorobots needed for future applications of nanomedicine.

Read this article:
Nanorobots in Medicine - Nanomedicine

Read More...

Nanobiotechnology – Wikipedia, the free encyclopedia

Thursday, August 27th, 2015

Nanobiotechnology, bionanotechnology, and nanobiology are terms that refer to the intersection of nanotechnology and biology.[1] Given that the subject is one that has only emerged very recently, bionanotechnology and nanobiotechnology serve as blanket terms for various related technologies.

This discipline helps to indicate the merger of biological research with various fields of nanotechnology. Concepts that are enhanced through nanobiology include: nanodevices (such as biological machines), nanoparticles, and nanoscale phenomena that occurs within the discipline of nanotechnology. This technical approach to biology allows scientists to imagine and create systems that can be used for biological research. Biologically inspired nanotechnology uses biological systems as the inspirations for technologies not yet created.[2] However, as with nanotechnology and biotechnology, bionanotechnology does have many potential ethical issues associated with it.

The most important objectives that are frequently found in nanobiology involve applying nanotools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptoid nanosheets, for medical and biological purposes is another primary objective in nanotechnology. New nanotools are often made by refining the applications of the nanotools that are already being used. The imaging of native biomolecules, biological membranes, and tissues is also a major topic for the nanobiology researchers. Other topics concerning nanobiology include the use of cantilever array sensors and the application of nanophotonics for manipulating molecular processes in living cells.[3]

Recently, the use of microorganisms to synthesize functional nanoparticles has been of great interest. Microorganisms can change the oxidation state of metals. These microbial processes have opened up new opportunities for us to explore novel applications, for example, the biosynthesis of metal nanomaterials. In contrast to chemical and physical methods, microbial processes for synthesizing nanomaterials can be achieved in aqueous phase under gentle and environmentally benign conditions. This approach has become an attractive focus in current green bionanotechnology research towards sustainable development.[4]

The terms are often used interchangeably. When a distinction is intended, though, it is based on whether the focus is on applying biological ideas or on studying biology with nanotechnology. Bionanotechnology generally refers to the study of how the goals of nanotechnology can be guided by studying how biological "machines" work and adapting these biological motifs into improving existing nanotechnologies or creating new ones.[5][6] Nanobiotechnology, on the other hand, refers to the ways that nanotechnology is used to create devices to study biological systems.[7]

In other words, nanobiotechnology is essentially miniaturized biotechnology, whereas bionanotechnology is a specific application of nanotechnology. For example, DNA nanotechnology or cellular engineering would be classified as bionanotechnology because they involve working with biomolecules on the nanoscale. Conversely, many new medical technologies involving nanoparticles as delivery systems or as sensors would be examples of nanobiotechnology since they involve using nanotechnology to advance the goals of biology.

The definitions enumerated above will be utilized whenever a distinction between nanobio and bionano is made in this article. However, given the overlapping usage of the terms in modern parlance, individual technologies may need to be evaluated to determine which term is more fitting. As such, they are best discussed in parallel.

Most of the scientific concepts in bionanotechnology are derived from other fields. Biochemical principles that are used to understand the material properties of biological systems are central in bionanotechnology because those same principles are to be used to create new technologies. Material properties and applications studied in bionanoscience include mechanical properties(e.g. deformation, adhesion, failure), electrical/electronic (e.g. electromechanical stimulation, capacitors, energy storage/batteries), optical (e.g. absorption, luminescence, photochemistry), thermal (e.g. thermomutability, thermal management), biological (e.g. how cells interact with nanomaterials, molecular flaws/defects, biosensing, biological mechanisms s.a. mechanosensing), nanoscience of disease (e.g. genetic disease, cancer, organ/tissue failure), as well as computing (e.g. DNA computing). The impact of bionanoscience, achieved through structural and mechanistic analyses of biological processes at nanoscale, is their translation into synthetic and technological applications through nanotechnology.

Nano-biotechnology takes most of its fundamentals from nanotechnology. Most of the devices designed for nano-biotechnological use are directly based on other existing nanotechnologies. Nano-biotechnology is often used to describe the overlapping multidisciplinary activities associated with biosensors, particularly where photonics, chemistry, biology, biophysics, nano-medicine, and engineering converge. Measurement in biology using wave guide techniques, such as dual polarization interferometry, are another example.

Applications of bionanotechnology are extremely widespread. Insofar as the distinction holds, nanobiotechnology is much more commonplace in that it simply provides more tools for the study of biology. Bionanotechnology, on the other hand, promises to recreate biological mechanisms and pathways in a form that is useful in other ways.

Nanomedicine is a field of medical science whose applications are increasing more and more thanks to nanorobots and biological machines, which constitute a very useful tool to develop this area of knowledge. In the past years, researchers have done many improvements in the different devices and systems required to develop nanorobots. This supposes a new way of treating and dealing with diseases such as cancer; thanks to nanorobots, side effects of chemotherapy have been controlled, reduced and even eliminated, so some years from now, cancer patients will be offered an alternative to treat this disease instead of chemotherapy, which causes secondary effects such as hair lose, fatigue or nausea killing not only cancerous cells but also the healthy ones. At a clinical level, cancer treatment with nanomedicine will consist on the supply of nanorobots to the patient through an injection that will seek for cancerous cells leaving untouched the healthy ones. Patients that will be treated through nanomedicine will not notice the presence of this nanomachines inside them; the only thing that is going to be noticeable is the progressive improvement of their health.[8]

Nanobiotechnology (sometimes referred to as nanobiology) is best described as helping modern medicine progress from treating symptoms to generating cures and regenerating biological tissues. Three American patients have received whole cultured bladders with the help of doctors who use nanobiology techniques in their practice. Also, it has been demonstrated in animal studies that a uterus can be grown outside the body and then placed in the body in order to produce a baby. Stem cell treatments have been used to fix diseases that are found in the human heart and are in clinical trials in the United States. There is also funding for research into allowing people to have new limbs without having to resort to prosthesis. Artificial proteins might also become available to manufacture without the need for harsh chemicals and expensive machines. It has even been surmised that by the year 2055, computers may be made out of biochemicals and organic salts.[9]

Another example of current nanobiotechnological research involves nanospheres coated with fluorescent polymers. Researchers are seeking to design polymers whose fluorescence is quenched when they encounter specific molecules. Different polymers would detect different metabolites. The polymer-coated spheres could become part of new biological assays, and the technology might someday lead to particles which could be introduced into the human body to track down metabolites associated with tumors and other health problems. Another example, from a different perspective, would be evaluation and therapy at the nanoscopic level, i.e. the treatment of Nanobacteria (25-200nm sized) as is done by NanoBiotech Pharma.

While nanobiology is in its infancy, there are a lot of promising methods that will rely on nanobiology in the future. Biological systems are inherently nano in scale; nanoscience must merge with biology in order to deliver biomacromolecules and molecular machines that are similar to nature. Controlling and mimicking the devices and processes that are constructed from molecules is a tremendous challenge to face the converging disciplines of nanotechnology.[10] All living things, including humans, can be considered to be nanofoundries. Natural evolution has optimized the "natural" form of nanobiology over millions of years. In the 21st century, humans have developed the technology to artificially tap into nanobiology. This process is best described as "organic merging with synthetic." Colonies of live neurons can live together on a biochip device; according to research from Dr. Gunther Gross at the University of North Texas. Self-assembling nanotubes have the ability to be used as a structural system. They would be composed together with rhodopsins; which would facilitate the optical computing process and help with the storage of biological materials. DNA (as the software for all living things) can be used as a structural proteomic system - a logical component for molecular computing. Ned Seeman - a researcher at New York University - along with other researchers are currently researching concepts that are similar to each other.[11]

DNA nanotechnology is one important example of bionanotechnology.[12] The utilization of the inherent properties of nucleic acids like DNA to create useful materials is a promising area of modern research. Another important area of research involves taking advantage of membrane properties to generate synthetic membranes. Proteins that self-assemble to generate functional materials could be used as a novel approach for the large-scale production of programmable nanomaterials. One example is the development of amyloids found in bacterial biofilms as engineered nanomaterials that can be programmed genetically to have different properties.[13]Protein folding studies provide a third important avenue of research, but one that has been largely inhibited by our inability to predict protein folding with a sufficiently high degree of accuracy. Given the myriad uses that biological systems have for proteins, though, research into understanding protein folding is of high importance and could prove fruitful for bionanotechnology in the future.

Lipid nanotechnology is another major area of research in bionanotechnology, where physico-chemical properties of lipids such as their antifouling and self-assembly is exploited to build nanodevices with applications in medicine and engineering.[14]

This field relies on a variety of research methods, including experimental tools (e.g. imaging, characterization via AFM/optical tweezers etc.), x-ray diffraction based tools, synthesis via self-assembly, characterization of self-assembly (using e.g. dual polarization interferometry, recombinant DNA methods, etc.), theory (e.g. statistical mechanics, nanomechanics, etc.), as well as computational approaches (bottom-up multi-scale simulation, supercomputing).

Continued here:
Nanobiotechnology - Wikipedia, the free encyclopedia

Read More...

Center for Drug Delivery and Nanomedicine (CDDN)

Saturday, August 15th, 2015

The need for the discovery and development of innovative technologies to improve the delivery of therapeutic and diagnostic agents in the body is widely recognized. The next generation therapies must be able to deliver drugs, therapeutic proteins and recombinant DNA to focal areas of disease or to tumors to maximize clinical benefit while limiting untoward side effects. The use of nanoscale technologies to design novel drug delivery systems and devices is a rapidly developing area of biomedical research that promises breakthrough advances in therapeutics and diagnostics.

Center for Drug Delivery and Nanomedicine (CDDN) serves to unify existing diverse technical and scientific expertise in biomedical and material science research at the University of Nebraska thereby creating a world class interdisciplinary drug delivery and nanomedicine program. This is realized by integrating established expertise in drug delivery, gene therapy, neuroscience, pathology, immunology, pharmacology, vaccine therapy, cancer biology, polymer science and nanotechnology at the University of Nebraska Medical Center (UNMC), the University of Nebraska at Lincoln (UNL) and Creighton University.

CDDNs vision is to improve health by enhancing the efficacy and safety of new and existing therapeutic agents, diagnostic agents and genes through the discovery and application of innovative methods of drug delivery and nanotechnology. CDDNs mission is to discover and apply knowledge to design, develop and evaluate novel approaches to improve the delivery of therapeutic agents, diagnostic agents and genes.

The COBRE Nebraska Center for Nanomedicine is supported by the National Institute of General Medical Science(NIGMS) grant 2P20 GM103480-07.

Read this article:
Center for Drug Delivery and Nanomedicine (CDDN)

Read More...

IBMs nanomedicine initiative – IBM Research: Overview

Saturday, July 4th, 2015

Creating a hydrogel from the polymers

Through the precise tailoring of the ninja polymers, researchers were able to create macromolecules - molecular structures containing a large number of atoms - which combine water solubility, a positive charge, and biodegradability. When mixed with water and heated to normal body temperature, the polymers self-assemble, swelling into a synthetic hydrogel that is easy to manipulate.

When applied to contaminated surfaces, the hydrogel's positive charge attracts negatively charged microbial membranes, like stars and planets being pulled into a black hole. However, unlike other antimicrobials that target the internal machinery of bacteria to try to prevent it from replicating, this hydrogel destroys the bacteria by rupturing the bacteria's membrane, rendering it completely unable to regenerate or spread.

The hydrogel is comprised of more than 90 percent water, making it easy to handle and apply to surfaces. It also makes it potentially viable for eventual inclusion in applications like creams or injectable therapeutics for wound healing, implant and catheter coatings, skin infections or even orifice barriers. It is the first-ever to be biodegradable, biocompatible and non-toxic, potentially making it an ideal tool to combat serious health hazards facing hospital workers, visitors and patients.

The IBM scientists in the nanomedicine polymer program along with the Institute of Bioengineering and Nanotechnology have taken this research a step further and have made a nanomedicine breakthrough in which they converted common plastic materials like polyethylene terephthalate (PET) into non-toxic and biocompatible materials designed to specifically target and attack fungal infections.BCC Research reported that the treatment cost for fungal infections was $3 billion worldwide in 2010 andis expected to increase to $6 billion in 2014. In this breakthrough, the researchers identified a novel self-assembly process for broken down PET, the primary material in plastic water bottles, in which 'super' molecules are formed through a hydrogen bond and serve as drug carriers targeting fungal infections in the body. Demonstrating characteristics like electrostatic charge similar to polymers, the molecules are able to break through bacterial membranes and eradicate fungus, then biodegrade in the body naturally. This is important to treat eye infections associated with contact lenses, and bloodstream infections like Candida.

See more here:
IBMs nanomedicine initiative - IBM Research: Overview

Read More...

Wiley Interdisciplinary Reviews: Nanomedicine and …

Saturday, July 4th, 2015

Impact Factor: 4.239 Read, cite the journal, or submit your paper to keep contributing to the success of WIREs Nanomedicine and Nanobiotechnology

NanoMedicine-2013 is a dedicated event for the nanotech community and aims to offer professionals in the field a multidisciplinary platform to learn more about the latest scientific updates and industrial standards. Nanomedicine-2013 will consist of six tracks covering current advances in many aspects of nano-medicine R & D and business. The conference will consist of keynote forum, panel discussions, free communication, poster presentations and an exhibition. Through these dynamic scientific and social events, you will have many opportunities to network and to form potential business collaborations with participants from all over the world.

From 2012 (Volume 4), access to the full content of WIREs Nanomedicine and Nanobiotechnology is through a subscription only. Subscribe here or use our easy online library recommendation form to recommend this title to your librarian today.

If your institution opted-in last year, you will retain access to content back to 2009, including all of our special collections.

Never miss an issue! Get the table of contents emailed to your inbox for free each time an issue is published online. Under Journal Tools:

And don't forget to follow us on

!

See the original post here:
Wiley Interdisciplinary Reviews: Nanomedicine and ...

Read More...

Nano Medicine – Treatments for Antibiotic Resistant Bacteria

Friday, June 5th, 2015

Antibiotic resistance is now a bigger crisis than the AIDS epidemic of the 1980s, a landmark report recently warned. The spread of deadly superbugs that evade even the most powerful antibiotics is happening across the world, United Nations officials have confirmed. The effects will be devastating meaning a simple scratch or urinary tract infection could kill.

Tuberculosis (TB) is a scourge that is threatening to get ugly because TB is usually cured by taking antibiotics for six to nine months. However, if that treatment is interrupted or the dose is cut down, the stubborn bacteria battle back and mutate into a tougher strain that can no longer be killed by drugs. Such strains are scaring the heck out of the medical community for good reason. Tuberculosis is highly contagious, holding the potential to wipe out wide swaths of humanity in the case of an epidemic of these drug resistant strains.

Australias first victim of a killer strain of drug-resistant tuberculosis died amid warnings of a looming health epidemic on Queenslands doorstep. Medical experts are seriously concerned about the handling of the TB epidemic in Papua New Guinea after Catherina Abraham died of an incurable form of the illness, known as XDR-TB (extensively drug resistant TB) in Cairns Base Hospital. Of course we always get big scares from the mainstream medical press, who are big cheerleaders of big pharmaceutical companies as our governmental medical officials.

Now medical experts are warning that drug resistant tuberculosis is such a problem in the Asia Pacific region that it could overwhelm health systems.

A drug-resistant TB case did touch off a scare in U.S. We dont know too much about a Nepalese man whos in medical isolation in Texas while being treated for extensively drug-resistant tuberculosis, or XDR-TB, the most difficult-to-treat kind.

XDR-TB is resistant not only to isoniazid and rifampin but also a class of drugs called fluoroquinolones and one or more potent injectable antibiotics. This is one of the nastiest of all antibiotics, which easily destroys peoples lives by itself.

TB germs become drug-resistant when patients fail to complete a course of treatment. When a partly-resistant strain is treated with the wrong drugs, it can become extensively resistant. There are about 60,000 people with XDR-TB strains like the Nepalese man whos in isolation. That means there are other people with XDR-TB traveling the world at any given time.

China and India Will Spread TB around the World

Original post:
Nano Medicine - Treatments for Antibiotic Resistant Bacteria

Read More...

Nanomedicine, bionanotechnology | NanomedicineCenter.com

Monday, June 1st, 2015

A lot of patients suffering from colon cancer might well present no symptoms or signs during the earliest stages of the condition. When symptoms do eventually present, they can be many and varied, and can very much depend upon the size of the affliction, how far it has spread and also its actual location. It might be that some symptoms that present are as a result of a condition other than cancer itself, ranging from irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and occasionally diverticulosis. Also, such problems as abdominal pain or swelling can be symptomatic of colon problems and may well require further investigation.

You may also notice that, upon going to the lavatory, you have some blood in your stools, and this can be a symptom of cancer. Of course, having black poop doesnt ultimately mean that cancer is present. It can, however, also be indicative of other conditions and problems. For example, the kind of bright red blood that you may see on your toilet tissue could be as a result of hemorrhoids or anal fissures. It should also be remembered that various food items can also result in red poop, and these include beetroot and red liquorice. Some medications can also be culprits, and some can also turn the stools black-including iron supplements. Irrespective, any sign of blood or change in your stools should prompt you to seek advice from your GP, as it is always best to be sure that it is not a sign of a more serious condition, and with any cancer,early detection and treatment is essential to a successful recovery.

You should also note-if you are currently concerned-any change in the regularity of your stools-including whether or not they are more thin or irregular than usual-especially over a period of several weeks. Also, be mindful if you have diarrhea for several days in a row or, conversely, constipation.

You might also experience pain in your lower abdomen-including a feeling of hardness. You may also experience persistent pain or discomfort in your abdominal region, and this can include wind and cramps. You may also get the sensation that, when evacuating your bowels, that the bowel doesnt empty fully. Another symptom that you might recognize is colored stool mainly black stool, but could be green stool too. Also, if you have an iron deficiency (or anemia), it may be an indication that there is bleeding in your colon. Also, as in most cases and types of cancer, you should seek medical advice immediately if you experience any sudden and unexpected or unexplained weight loss, as this is one of the principal red flags. Also be aware of more vague, seemingly incidental symptoms, such as fatigue. IF you have a couple of symptoms and also feel fatigued for days in a row inexplicably, then this is also another warning sign and you should seek medical advice. It is important not to panic, but just to be aware of what might be going on.

Remember, cases of colon cancer account for around 90% of all cases of intestinal cancers, and also account for more deaths every year of men and women from cancer. Early treatment is an absolute must.

Read more from the original source:
Nanomedicine, bionanotechnology | NanomedicineCenter.com

Read More...

Nano Medicine

Monday, May 25th, 2015

May 21st, 2015 Filed under Magnetic Resonance Imaging Tagged angelo-mosso, animals, balance, bold, cambridge, energy, gradient, magnetic, nuclei, proportion, redistribution, study, the-brain Comments Off on Functional magnetic resonance imaging Wikipedia, the

FMRI redirects here. For Fault Management Resource Identifier, see OpenBSM.

Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow.[1][2] This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.[3]

The primary form of fMRI uses the blood-oxygen-level dependent (BOLD) contrast,[4] discovered by Seiji Ogawa. This is a type of specialized brain and body scan used to map neural activity in the brain or spinal cord of humans or other animals by imaging the change in blood flow (hemodynamic response) related to energy use by brain cells.[4] Since the early 1990s, fMRI has come to dominate brain mapping research because it does not require people to undergo shots, surgery, or to ingest substances, or be exposed to radiation, etc.[5] Other methods of obtaining contrast are arterial spin labeling [6] and diffusion MRI.

The procedure is similar to MRI but uses the change in magnetization between oxygen-rich and oxygen-poor blood as its basic measure. This measure is frequently corrupted by noise from various sources and hence statistical procedures are used to extract the underlying signal. The resulting brain activation can be presented graphically by color-coding the strength of activation across the brain or the specific region studied. The technique can localize activity to within millimeters but, using standard techniques, no better than within a window of a few seconds.[citation needed]

fMRI is used both in the research world, and to a lesser extent, in the clinical world. It can also be combined and complemented with other measures of brain physiology such as EEG and NIRS. Newer methods which improve both spatial and time resolution are being researched, and these largely use biomarkers other than the BOLD signal. Some companies have developed commercial products such as lie detectors based on fMRI techniques, but the research is not believed to be ripe enough for widespread commercialization.[7]

The fMRI concept builds on the earlier MRI scanning technology and the discovery of properties of oxygen-rich blood. MRI brain scans use a strong, permanent, static magnetic field to align nuclei in the brain region being studied. Another magnetic field, the gradient field, is then applied to kick the nuclei to higher magnetization levels, with the effect depending on where they are located. When the gradient field is removed, the nuclei go back to their original states, and the energy they emit is measured with a coil to recreate the positions of the nuclei. MRI thus provides a static structural view of brain matter. The central thrust behind fMRI was to extend MRI to capture functional changes in the brain caused by neuronal activity. Differences in magnetic properties between arterial (oxygen-rich) and venous (oxygen-poor) blood provided this link.[8]

Since the 1890s it has been known that changes in blood flow and blood oxygenation in the brain (collectively known as hemodynamics) are closely linked to neural activity.[9] When neurons become active, local blood flow to those brain regions increases, and oxygen-rich (oxygenated) blood displaces oxygen-depleted (deoxygenated) blood around 2 seconds later. This rises to a peak over 46 seconds, before falling back to the original level (and typically undershooting slightly). Oxygen is carried by the hemoglobin molecule in red blood cells. Deoxygenated hemoglobin (dHb) is more magnetic (paramagnetic) than oxygenated hemoglobin (Hb), which is virtually resistant to magnetism (diamagnetic). This difference leads to an improved MR signal since the diamagnetic blood interferes with the magnetic MR signal less. This improvement can be mapped to show which neurons are active at a time.[10]

During the late 19th century, Angelo Mosso invented the human circulation balance, which could non-invasively measure the redistribution of blood during emotional and intellectual activity.[11] However, although briefly mentioned by William James in 1890, the details and precise workings of this balance and the experiments Mosso performed with it have remained largely unknown until the recent discovery of the original instrument as well as Mossos reports by Stefano Sandrone and colleagues.[12]Angelo Mosso investigated several critical variables that are still relevant in modern neuroimaging such as the signal-to-noise ratio, the appropriate choice of the experimental paradigm and the need for the simultaneous recording of differing physiological parameters.[12] Mossos manuscripts do not provide direct evidence that the balance was really able to measure changes in cerebral blood flow due to cognition,[12] however a modern replication performed by David T Field[13] has now demonstrated using modern signal processing techniques unavailable to Mosso that a balance apparatus of this type is able detect changes in cerebral blood volume related to cognition.

In 1890, Charles Roy and Charles Sherrington first experimentally linked brain function to its blood flow, at Cambridge University.[14] The next step to resolving how to measure blood flow to the brain was Linus Paulings and Charles Coryells discovery in 1936 that oxygen-rich blood with Hb was weakly repelled by magnetic fields, while oxygen-depleted blood with dHb was attracted to a magnetic field, though less so than ferromagnetic elements such as iron. Seiji Ogawa at AT&T Bell labs recognized that this could be used to augment MRI, which could study just the static structure of the brain, since the differing magnetic properties of dHb and Hb caused by blood flow to activated brain regions would cause measurable changes in the MRI signal. BOLD is the MRI contrast of dHb, discovered in 1990 by Ogawa. In a seminal 1990 study based on earlier work by Thulborn et al., Ogawa and colleagues scanned rodents in a strong magnetic field (7.0T) MRI. To manipulate blood oxygen level, they changed the proportion of oxygen the animals breathed. As this proportion fell, a map of blood flow in the brain was seen in the MRI. They verified this by placing test tubes with oxygenated or deoxygenated blood and creating separate images. They also showed that gradient-echo images, which depend on a form of loss of magnetization called T2* decay, produced the best images. To show these blood flow changes were related to functional brain activity, they changed the composition of the air breathed by rats, and scanned them while monitoring brain activity with EEG.[15] The first attempt to detect the regional brain activity using MRI was performed by Belliveau and others at Harvard University using the contrast agent Magnevist, a ferromagnetic substance remaining in the bloodstream after intravenous injection. However, this method is not popular in human fMRI, because any medically unnecessary injection is to a degree unsafe and uncomfortable, and because the agent stays in the blood only for a short time. [16]

Read the original:
Nano Medicine

Read More...

Nanomedicine – Wikipedia, the free encyclopedia

Wednesday, May 20th, 2015

Nanomedicine is the medical application of nanotechnology.[1] Nanomedicine ranges from the medical applications of nanomaterials, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials (materials whose structure is on the scale of nanometers, i.e. billionths of a meter).

Functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. The size of nanomaterials is similar to that of most biological molecules and structures; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical research and applications. Thus far, the integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug delivery vehicles.

Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices in the near future.[2][3] The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging.[4] Nanomedicine research is receiving funding from the US National Institutes of Health, including the funding in 2005 of a five-year plan to set up four nanomedicine centers.

Nanomedicine is a large industry, with nanomedicine sales reaching $6.8 billion in 2004, and with over 200 companies and 38 products worldwide, a minimum of $3.8 billion in nanotechnology R&D is being invested every year.[5] In April 2006, the journal Nature Materials estimated that 130 nanotech-based drugs and delivery systems were being developed worldwide.[6] As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.

Nanotechnology has provided the possibility of delivering drugs to specific cells using nanoparticles.

The overall drug consumption and side-effects may be lowered significantly by depositing the active agent in the morbid region only and in no higher dose than needed. Targeted drug delivery is intended to reduce the side effects of drugs with concomitant decreases in consumption and treatment expenses. Drug delivery focuses on maximizing bioavailability both at specific places in the body and over a period of time. This can potentially be achieved by molecular targeting by nanoengineered devices.[7][8] More than $65 billion are wasted each year due to poor bioavailability.[citation needed] A benefit of using nanoscale for medical technologies is that smaller devices are less invasive and can possibly be implanted inside the body, plus biochemical reaction times are much shorter. These devices are faster and more sensitive than typical drug delivery.[9] The efficacy of drug delivery through nanomedicine is largely based upon: a) efficient encapsulation of the drugs, b) successful delivery of drug to the targeted region of the body, and c) successful release of the drug.[citation needed]

Drug delivery systems, lipid- [10] or polymer-based nanoparticles,[11] can be designed to improve the pharmacokinetics and biodistribution of the drug.[12][13][14] However, the pharmacokinetics and pharmacodynamics of nanomedicine is highly variable among different patients.[15] When designed to avoid the body's defence mechanisms,[16] nanoparticles have beneficial properties that can be used to improve drug delivery. Complex drug delivery mechanisms are being developed, including the ability to get drugs through cell membranes and into cell cytoplasm. Triggered response is one way for drug molecules to be used more efficiently. Drugs are placed in the body and only activate on encountering a particular signal. For example, a drug with poor solubility will be replaced by a drug delivery system where both hydrophilic and hydrophobic environments exist, improving the solubility.[17] Drug delivery systems may also be able to prevent tissue damage through regulated drug release; reduce drug clearance rates; or lower the volume of distribution and reduce the effect on non-target tissue. However, the biodistribution of these nanoparticles is still imperfect due to the complex host's reactions to nano- and microsized materials[16] and the difficulty in targeting specific organs in the body. Nevertheless, a lot of work is still ongoing to optimize and better understand the potential and limitations of nanoparticulate systems. While advancement of research proves that targeting and distribution can be augmented by nanoparticles, the dangers of nanotoxicity become an important next step in further understanding of their medical uses.[18]

Nanoparticles can be used in combination therapy for decreasing antibiotic resistance or for their antimicrobial properties.[19][20][21] Nanoparticles might also used to circumvent multidrug resistance (MDR) mechanisms.[22]

Two forms of nanomedicine that have already been tested in mice and are awaiting human trials that will be using gold nanoshells to help diagnose and treat cancer,[23] and using liposomes as vaccine adjuvants and as vehicles for drug transport.[24][25] Similarly, drug detoxification is also another application for nanomedicine which has shown promising results in rats.[26] Advances in Lipid nanotechnology was also instrumental in engineering medical nanodevices and novel drug delivery systems as well as in developing sensing applications.[27] Another example can be found in dendrimers and nanoporous materials. Another example is to use block co-polymers, which form micelles for drug encapsulation.[11]

Polymeric nano-particles are a competing technology to lipidic (based mainly on Phospholipids) nano-particles. There is an additional risk of toxicity associated with polymers not widely studied or understood. The major advantages of polymers is stability, lower cost and predictable characterisation. However, in the patient's body this very stability (slow degradation) is a negative factor. Phospholipids on the other hand are membrane lipids (already present in the body and surrounding each cell), have a GRAS (Generally Recognised As Safe) status from FDA and are derived from natural sources without any complex chemistry involved. They are not metabolised but rather absorbed by the body and the degradation products are themselves nutrients (fats or micronutrients).

More:
Nanomedicine - Wikipedia, the free encyclopedia

Read More...

IGERT Nanomedicine at Northeastern University

Wednesday, May 20th, 2015

STUDENT SPOTLIGHT

IGERT HIGHLIGHT

NSF Renews IGERT Nanomedicine PhD Program! 2010-2015

We are pleased to announce that the IGERT Nanomedicine Program has been renewed for an additional term 2010-2015. The new $3.1M IGERT Nanomedicine project leverages the success of the current Nanomedicine program at Northeastern to establish a global research and educational partnership between collaborators at Northeastern, University of Puerto Rico Mayaguez, Tuskegee University, collaborators at Harvard Medical School hospitals, and foreign partners including universities in Naples, Sao Paulo, York and Delhi.

MISSION

IGERT Nanomedicine Science and Technology is a new integrated doctoral education program in the emerging field of Nanomedicine, created with support from the National Cancer Institute and the National Science Foundation. The program aims to educate the next generation of scientists and technologists with the requisite skill sets to address scientific and engineering challenges, with the necessary business, ethical and global perspectives that will be needed in the rapidly emerging area of applying nanotechnology to human health.

The program began at Northeastern University in 2005 with an NSF IGERT grant funded through the National Cancer Institute. The success of the program has since then led to an NSF funded IGERT renewal grant for the period 2010-2015 with new partners, Tuskegee University, The University of Puerto Rico Mayaguez and collaborators at hospitals affiliated with Harvard Medical School.

The program combines the interdisciplinary expertise of world-renowned faculty members in 11 departments at 3 Universities, collaborating with researchers at teaching hospitals and industry. Students enrolled in a Ph.D. program in Biology, Chemistry, Physics, Chemical Engineering, Mechanical/Industrial Engineering, Electrical/Computer Engineering, or Pharmaceutical Sciences (Northeastern University), Materials Science and Engineering or Integrative Biosciences (Tuskegee University), Applied Chemistry or Chemical Engineering (UPRM) may apply to the IGERT interdisciplinary program. The IGERT fellow will graduate with a Ph.D. degree in their core subject with specialization in Nanomedicine Science and Technology.

Download the IGERT Nanomedicine e-book summarizing the achievements of the Northeastern University IGERT Nanomedicine program

More here:
IGERT Nanomedicine at Northeastern University

Read More...

Nanotechnology in Medicine – Nanomedicine

Wednesday, May 20th, 2015

The use of nanotechnology in medicine offers some exciting possibilities. Some techniques are only imagined, while others are at various stages of testing, or actually being used today.

Nanotechnology in medicine involves applications of nanoparticles currently under development, as well as longer range research that involves the use of manufactured nano-robots to make repairs at the cellular level (sometimes referred to as nanomedicine).

Whatever you call it, the use of nanotechnology in the field of medicine could revolutionize the way we detect and treat damage to the human body and disease in the future, and many techniques only imagined a few years ago are making remarkable progress towards becoming realities.

One application of nanotechnology in medicine currently being developed involves employing nanoparticles to deliver drugs, heat, light or other substances to specific types of cells (such as cancer cells). Particles are engineered so that they are attracted to diseased cells, which allowsdirect treatment of those cells. This technique reduces damage to healthy cells in the body and allows for earlier detection of disease.

For example, nanoparticles that deliver chemotherapy drugs directly to cancer cells are under development. Tests are in progress for targeted delivery of chemotherapy drugs and their final approval for their use with cancer patients is pending. One company, CytImmune has published the results of a Phase 1 Clinical Trial of their first targeted chemotherapy drug and another company, BIND Biosciences, has published preliminary results of a Phase 1 Clinical Trial for their first targeted chemotherapy drug and is proceeding with a Phase 2 Clinical Trial.

Researchers at the University of Illinois have demonstated that gelatin nanoparticles can be used to deliver drugs to damaged brain tissue.

Researchers at MIT using nanoparticles to deliver vaccine.The nanoparticles protect the vaccine, allowing the vaccine time to trigger a stronger immune response.

Reserchers are developing a method to release insulin that uses a sponge-like matrix that contains insulin as well as nanocapsules containing an enzyme. When the glucose level rises the nanocapsules release hydrogen ions, which bind to the fibers making up the matrix. The hydrogen ions make the fibers positively charged, repelling each other and creating openings in the matrix through which insulin is released.

Researchers are developing a nanoparticle that can be taken orally and pass through the lining of the intestines into the bloodsteam. This should allow drugs that must now be delivered with a shot to be taken in pill form.

Researchers are also developing a nanoparticle to defeat viruses. The nanoparticle does not actually destroy viruses molecules, but delivers an enzyme that prevents the reproduction of viruses molecules in the patients bloodstream.

See the rest here:
Nanotechnology in Medicine - Nanomedicine

Read More...

Nanomedicine

Tuesday, May 19th, 2015

This site uses cookies to improve performance. If your browser does not accept cookies, you cannot view this site.

There are many reasons why a cookie could not be set correctly. Below are the most common reasons:

This site uses cookies to improve performance by remembering that you are logged in when you go from page to page. To provide access without cookies would require the site to create a new session for every page you visit, which slows the system down to an unacceptable level.

This site stores nothing other than an automatically generated session ID in the cookie; no other information is captured.

In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a website to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it.

Read the original here:
Nanomedicine

Read More...

Home [clinam.org]

Tuesday, May 19th, 2015

The European Summit for Clinical Nanomedicine and Targeted Medicine - The Translation to Knowledge Based Nanomedicine

Eighth Conference And Exhibition, June 28 - July 1, 2015

Sunday, June 28, 2015 General Assembly of the European Society for Nanomedicine (15.30 h) Meeting of the International Society for Nanomedicine (16.30 h) Editorial Board Meeting, European Journal of Nanomedicine (18.00 h) Welcome Dinner for Speakers & invited Guests [19.45 Swisstel Le Plaza, 1st Floor]

Co-founded by the Swiss Confederation. Swiss Derpartment of Economic Affairs, Education and Research

Scientific Committee: Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (Chairman) Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) Dr. med. h.c. Beat Lffler, MA, European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH) Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (GB) Prof. Dr. med. Janos Szebeni, Bay Zoltan Ltd and Semmelweis/Miskolc Universities, Budapest (HU) Prof. Dr. med. Christoph Alexiou, Head and Neck Surgery, University Hospital Erlangen (D) Prof. Dr. Claus-Michael Lehr, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarbrucken (D) Prof. Dr. Gerd Binnig, Founder of Definiens AG, Nobel Laureate, Munich (DE) Patrick Boisseau, CEA-Lti, Chairman of the ETPN, Grenoble (FR) Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zrich (CH) Prof. Dr. Jan Mollenhauer, Director Lundbeckfonden Center of Excellence University of Southern Denmark, Odense (DK) Dr. Yanay Ofran, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)

Conference Venue: Congress Center, Messeplatz 21, 4058 Basel, Switzerland, Phone + 41 58 206 28 28 This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow this link:
Home [clinam.org]

Read More...

Regenerative Medicine Biotech Company, Eqalix, Names Scientific Advisory Board

Tuesday, October 9th, 2012

Eqalix Inc., an emerging regenerative medicine company, announces its Scientific Advisory Board (SAB). This SAB gives Eqalix a depth and breadth of experience necessary to take it to the next level.

Reston, VA (PRWEB) October 09, 2012

"We are very pleased to bring together these key thought leaders to establish the Eqalix Scientific Advisory Board," stated Joseph P. Connell, Eqalix CEO and Chairman of the Board. "I have worked with Drs. Gold and Goldman for years and have always admired their abilities. Dr Lelkes technologies will make a profound impact upon aesthetic dermatology, wound healing and regenerating blood vessels, nerve endings and damaged organs with the guidance of this distinguished panel. It is not clich in any manner when I say that we are thrilled to work with this team. We look to their guidance, industry knowledge and network to help deliver these therapies into clinic and prospective patients as soon as possible, as I am confident our technologies will make a difference, said Connell.

The members of the Eqalix Scientific Advisory Board are:

Peter I. Lelkes, PhD: Chief Scientific Advisor; Dr. Lelkes is the Laura H. Carnell Professor and Founding Chair of the Department of Bioengineering in the College of Engineering at Temple University and the Inaugural Director of the Institute for Regenerative Medicine and Engineering (TIME) at Temple Universitys School of Medicine. While at Drexel, Prof. Lelkes directed an interdisciplinary program in tissue engineering and regenerative medicine, focusing on nanotechnology-based biomaterials and soft tissue engineering, employing developmental biological principles to enhance the tissue-specific differentiation of embryonic and adult stem cells. Dr. Lelkes has organized several Keystone conferences and published more than 160 peer-reviewed papers and 45 book chapters and made more than 400 presentations nationally and internationally.

Dr. Lelkes basic and translational research has been support by federal (NIH, NSF, NASA, DOE) and state funding agencies, (NTI and Dept. of Commerce, Tobacco Settlement Funds) and private Foundations, including the Coulter Foundation. Most recently, Dr. Lelkes has been named Director of the Surgical Engineering Enterprise, one of the major initiatives of the strategic plan of Drexel Universitys College of Medicine. In addition, Dr. Lelkes has been the team leader for tissue engineering at the Nanotechnology Institute of Southeastern Pennsylvania (NTI) and is the Co-Director of PATRIC, the Pennsylvania Advanced Textile Research and Innovation Center, focusing on BioNanoTextiles and Stem Cell Biology.

Dr Lelkes stated, "I am delighted and excited to partner with Eqalix to translate our inventions from the bench to the bedside in a timely fashion.

Mitchel P. Goldman, MD, Scientific Advisor, Founder and Medical Director of Goldman Butterwick Fitzpatrick, Groff & Fabi, Cosmetic Laser Dermatology. A graduate of Boston University, Summa Cum Laude, and the Stanford University Medical School, Dr. Goldman is a Volunteer Clinical Professor in Medicine/Dermatology at the University of California, San Diego. Dr Goldman is Board Certified by both the American Board of Dermatology and the American Board of Cosmetic Surgery.

He is a fellow of the American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, American Academy of Cosmetic Surgery and the American Society of Liposuction Surgery. He is former President of the American College of Phlebology and President-Elect of the American Society for Dermatologic Surgery. He presently serves on the Board of Trustees for the American Academy of Cosmetic Surgery. He also has authored and/or co-authored 21 Textbooks on Dermatology, Sclerotherapy, Ambulatory Phlebectomy, Cutaneous Laser Surgery, Cellulite and Dermatologic Surgery as well as over 300 peer-reviewed publications and textbook chapters.

Dr Goldman added: I am very interested and excited to work with the Eqalix team to make these technologies a success. I believe that my background lends well to truly shaping the successful commercialization of these products for my patients to improve outcomes.

Original post:
Regenerative Medicine Biotech Company, Eqalix, Names Scientific Advisory Board

Read More...

U.S. and Canadian Scientists Form a Global Alliance for Nano-Bio-Electronics in Order to Rapidly Find Solutions for …

Tuesday, February 14th, 2012

LOS ANGELES, Feb. 13, 2012 /PRNewswire/ -- The Society for Brain Mapping and Therapeutics (SBMT) announced today that the organization will hold its 9th Annual World Congress on Brain, Spinal Cord Mapping, and Image Guided Therapy from June 2-4, 2012 in Toronto, Canada.  The world's top brain and spinal cord scientists and surgeons will converge on the Toronto Metro Convention Center to find solutions to some of the most difficult to treat neurological disorders, including traumatic brain and spinal cord injuries, Parkinson's Disease, Alzheimer's Disease, and neurological cancers. 

The 2012 World Congress of SBMT is jointly supported by the American Association of Neurological Surgeons, the Government of Canada, the University of Toronto, and MaRS innovation; it is endorsed by the International Society for Magnetic Resonance Imaging in Medicine.

The theme of this year's World Congress is "Nano-Bio-Electronics," which focuses on the integration of nanotechnology, stem cell research, and biomedical engineering, and imaging of the brain and spinal cord to make progress in the fight against neurological diseases. The aim of the Congress is to provide a multidisciplinary forum for health professionals in the fields of neurosurgery, neurology, psychiatry, radiology, neuroscience, engineering, as well as policymakers, to collaborate as a global alliance to rapidly advance treatment of neurological disorders.

"The meeting will help us kick start a unique and efficient consortium, which will unite scientists and consolidate resources in order to help us quickly come up with solutions for the devastating neurological diseases affecting millions and costing billions in the US alone," said Babak Kateb, Chairman of the Board of SBMT, President of the Brain Mapping Foundation, and Director of the National Center for Nano-Bio-Electronics (NCNBE). Dr. Kateb states, "The purpose of the Nano-Bio-Electronic alliance is to facilitate integration of nanotechnology, Stem cell and cellular therapy with medical devices and imaging. This consortium will impact global biomedical science and healthcare delivery through national and international partnerships with governments, universities, leading organizations and industries."

Among the notable participants of the 2012 World Congress includes Canadian Surgeon General Hans W. Jung, U.S. Navy Surgeon General Matthew Nathan, and Canadian Parliament Member Kirsty Duncan.  Dr. Duncan, an advocate for brain research in Canada and a global voice for neuroscience initiatives, stated "I am honored to participate in this important conference.  It is vital that we work to enhance our understanding of brain health through research and collaboration."  She added, "We must also affirm our commitment to improving the quality of life of those who live with a brain condition and of their families and informal caregivers."

Toronto was chosen for this year's meeting because of the city's strong and globally-connected network of neuroscientists, biomedical engineers, and investors in the biomedical and nanotechnology fields.   Michael Fehlings, chairman of the local organizing committee, Professor of Neurosurgery, and Director of the Neuroscience Program at the University of Toronto, said "The meeting will showcase Canadian and international neuroscience talent in a broad range of disciplines and will highlight the latest advances in imaging, molecular and cellular mechanisms, bioengineering and surgical intervention."

Parimal Nathwani, Vice President of MaRS Innovation, added, "Forums like this represent an excellent opportunity for reviewing technologies and supporting collaboration across different institutions for more effective translation and commercialization opportunity."

The 9th Annual World Congress is still accepting abstract proposals for the meeting's workshops, lectures, and presentation sessions. Abstract submission  is open now until March 15th 2012.

For the full list of 2012 speakers to register, or support of the 9th Annual World Congress of SBMT on Brain, Spinal Cord Mapping, and Image-Guided Therapy, please visit http://www.worldbrainmapping.org  or call (310) 500-6196.

Society of Brain Mapping and Therapeutics
SBMT is a non-profit society organized for the purpose of encouraging basic and clinical scientists who are interested in areas of Brain Mapping and Intra-operative Surgical planning to improve the diagnosis, treatment and rehabilitation of patients afflicted with neurological disorders.

This society promotes the public welfare and improves patient care through the translation of new technologies into life saving diagnostic and therapeutic procedures. The society is committed to excellence in education, and scientific discovery. The society achieves its mission through multi-disciplinary collaborations with government agencies, patient advocacy groups, educational institutes and private sector (industry) as well as philanthropic organization. http://www.IBMISPS.org

University of Toronto Neuroscience Program
The University Of Toronto Faculty Of Medicine established the U of T Neuroscience Program (UTNP) as a new academic program and appointed Professor Michael G. Fehlings as its first Director on September 1, 2008. The UTNP is a robust, integrated and collaborative academic program in neurosciences that leverages the unparalleled health science network at the University of Toronto, which includes U of T's many departments and institutes, health science faculties, 9 fully-affiliated research hospitals and 20 community-affiliated hospitals and clinical care sites.

MaRS Innovation
MaRS Innovation provides an integrated commercialization platform that harnesses the economic potential of the exception discovery pipeline of 16 leading academic institutions in Ontario. MaRS Innovation is a not-for-profit organization with an independent industry- led board of directors, funded through the Government of Canada's Networks of Centres of Excellence, the Province of Ontario through the Ministry of Research and Innovation, and contributions of its member institutions. Designed to enhance the commercial output of Toronto's outstanding scientific research cluster, MaRS Innovation will make a significant contribution to Canada's economic outlook and the quality of life for Canadians and others around the world. MaRS Innovation will advance commercialization through industry partnerships, licensing and company creation. The MaRS Innovation mission is to put Canada on the global innovation stage, by better connection of research with industry and strengthening Canada's competitive capacity in the knowledge based business – in short, to launch a new generation of robust high growth Canadian companies.  www.marsinnovation.com

American Association of Neurological Surgeons
The American Association of Neurological Surgeons (AANS) is the organization that speaks for all of neurosurgery. The AANS is dedicated to advancing the specialty of neurological surgery in order to promote the highest quality of patient care.  http://aans.org

More here:
U.S. and Canadian Scientists Form a Global Alliance for Nano-Bio-Electronics in Order to Rapidly Find Solutions for ...

Read More...

I believe in Renewable Energy, and here’s why

Sunday, May 8th, 2011

Renewable energy (RE) is a subjective and divisive topic, one that is influenced by many factors, including corruption, greed and purposeful ignorance, scientific and technological advances, and simple entrepreneurial spirit vs. entrenched interests.

Here are some of the reasons that I believe that we will see RE replace old energy by the midpoint of this century:

* It has been estimated that an area 55 miles by 55 miles dedicated to current solar technologies could replace all the electrical generating power of coal and oil (in the US). Or an area 80x80 miles to replace oil, coal and natural gas. (Here in the US we have over 100,000 square miles of desert, so space isn’t a problem)

* Regarding storage technologies (1) for when the sun is down: consider the advances taking place in fuel cells, batteries (LI, redox flow batteries, and 1300-ton battery modules used for grid stabilization), flywheels, compressed air, ultracapacitors and the likelihood that we will also use battery powered vehicles as storage.

* Regarding “getting the power from the solar installation to the people” – consider advances in superconducting wire and other advanced materials which are very likely to enable cheap and efficient transmission of power from where ever it is generated to where ever it is needed.

* Rooftop and local solar: My solar powered home won’t have to worry about darkness; we’ll tap into the battery reserve, as will all rooftop solar installations. A small percentage of our overall use to be sure, but significant none the less.

And as for explicit subsidies: on a per-energy-unit basis, then yes, solar has received more subsidies than fossil fuels in the very recent past. However, on the amount that each of us taxpayers has spent in a recent five-year period, fossil fuels subsidies far exceed solar.

Estimates range: (2)

Coal subsidies = somewhere between $17B and $72B
Solar subsidies = somewhere between $500M and $5B

And let us not forget that coal subsidizes also include intangible (and often purposefully left out) costs for cleaning up the ecosystem, and the public health expenses associated with all of the damage that the mining and use of coal causes. (3)

In my opinion, at the end of the day it all boils down to two simple facts: 1) technological change is on a double exponential growth curve (4) and 2) simple entrepreneurial spirit.

While we certainly need to wean society off finite, dangerous, polluting resources like coal and oil, the earth can and may go to hell in a handbasket. However, I think that entrepreneurial spirit and the certain fact that there is a barrel of money to be made in renewable energy solutions suggests that we will see RE replace old energy by the midpoint of this century. (5)

(1) "Of the ten advanced energy storage technologies, eight have applications in storage for electric power utilities at some level of development, aiming to provide reliable, economic, and energy-efficient power back-up options." Technical Insights Analyst Miriam Nagel

A123 Systems currently sells 2MW to 200MW grid stabilization systems (battery systems). Being used for large-scale energy storage deployment to support wind and solar integration. Small in comparison to the overall needs, but just one of many rapidly improving technologies.

“If investments in the smart grid infrastructure continue, electric vehicles may become ubiquitous — both because of the economic and environmental sense they make for consumers, and because of the vast store of batteries that will be available to grid operators to balance out the intermittency of wind and solar resources.”

“There are several major studies and research showing how the United States could reach 100 percent renewable electricity by 2050. Over the next two decades, the continually rising costs of fossil fuels will make it prohibitive to continue burning them, so we’ll witness the overdue transition to a largely renewable system. Smart grid upgrades will feature two-way communication to consumer appliances, real-time pricing information, more efficient transmission infrastructure, and advanced battery and flywheel technologies to balance the inherent fluctuations of wind and solar resources.”

http://www.mnn.com/earth-matters/energy/blogs/quayle-hodek-a-young-ceo-running-with-the-wind?hpt=Sbin

(2) “What if solar got the same subsidies as coal?” (Oct 21, 2010)
http://cleantechnica.com/2010/10/21/what-if-solar-got-the-same-subsidies-as-coal/

Coal subsidies: The U.S. coal industry enjoyed subsidies of around $17 billion between 2002 and 2008, including tax credits for production of "nonconventional" fuels ($14.1 billion), tax breaks on coal royalties ($986 million), exploration, and development breaks ($342 million), according to a study by the Environmental Law Institute.

http://sierraclub.typepad.com/mrgreen/2010/03/does-the-coal-industry-get-subsidies.html

Solar and wind subsidies: So far, the government has handed out about $5.4 billion, according to the Energy Department.

http://money.cnn.com/2010/11/18/news/economy/renewable_energy_tax_credit/index.htm

(3) Very informative investigative article http://wonkroom.thinkprogress.org/2011/02/03/manchin-coal-subsidies/

(4) “Most long range forecasts of technical feasibility in future time periods dramatically underestimate the power of future technology because they are based on what I call the “intuitive linear” view of technological progress rather than the “historical exponential view.” To express this another way, it is not the case that we will experience a hundred years of progress in the twenty-first century; rather we will witness on the order of twenty thousand years of progress (at today’s rate of progress, that is).” Ray Kurzweil http://www.kurzweilai.net/the-law-of-accelerating-returns

(5) During the past 11 years, as the editor of the leading nanoscale technologies web portal, I read and posted over 50,000 articles about advanced and frequently mind-blowing technologies. I have closely followed the very rapid progress in our understanding and utilization of the unique properties of the nanoscale (which greatly differ from the properties that we already understand). At the very least, we are headed for a future that not one of us can predict; what we can predict is that we will undoubtedly see old myths about technologies shattered and changes beyond our current level of comprehension.

Read More...

I believe in Renewable Energy, and here’s why

Sunday, May 8th, 2011

Renewable energy (RE) is a subjective and divisive topic, one that is influenced by many factors, including corruption, greed and purposeful ignorance, scientific and technological advances, and simple entrepreneurial spirit vs. entrenched interests.

Here are some of the reasons that I believe that we will see RE replace old energy by the midpoint of this century:

* It has been estimated that an area 55 miles by 55 miles dedicated to current solar technologies could replace all the electrical generating power of coal and oil (in the US). Or an area 80x80 miles to replace oil, coal and natural gas. (Here in the US we have over 100,000 square miles of desert, so space isn’t a problem)

* Regarding storage technologies (1) for when the sun is down: consider the advances taking place in fuel cells, batteries (LI, redox flow batteries, and 1300-ton battery modules used for grid stabilization), flywheels, compressed air, ultracapacitors and the likelihood that we will also use battery powered vehicles as storage.

* Regarding “getting the power from the solar installation to the people” – consider advances in superconducting wire and other advanced materials which are very likely to enable cheap and efficient transmission of power from where ever it is generated to where ever it is needed.

* Rooftop and local solar: My solar powered home won’t have to worry about darkness; we’ll tap into the battery reserve, as will all rooftop solar installations. A small percentage of our overall use to be sure, but significant none the less.

And as for explicit subsidies: on a per-energy-unit basis, then yes, solar has received more subsidies than fossil fuels in the very recent past. However, on the amount that each of us taxpayers has spent in a recent five-year period, fossil fuels subsidies far exceed solar.

Estimates range: (2)

Coal subsidies = somewhere between $17B and $72B
Solar subsidies = somewhere between $500M and $5B

And let us not forget that coal subsidizes also include intangible (and often purposefully left out) costs for cleaning up the ecosystem, and the public health expenses associated with all of the damage that the mining and use of coal causes. (3)

In my opinion, at the end of the day it all boils down to two simple facts: 1) technological change is on a double exponential growth curve (4) and 2) simple entrepreneurial spirit.

While we certainly need to wean society off finite, dangerous, polluting resources like coal and oil, the earth can and may go to hell in a handbasket. However, I think that entrepreneurial spirit and the certain fact that there is a barrel of money to be made in renewable energy solutions suggests that we will see RE replace old energy by the midpoint of this century. (5)

(1) "Of the ten advanced energy storage technologies, eight have applications in storage for electric power utilities at some level of development, aiming to provide reliable, economic, and energy-efficient power back-up options." Technical Insights Analyst Miriam Nagel

A123 Systems currently sells 2MW to 200MW grid stabilization systems (battery systems). Being used for large-scale energy storage deployment to support wind and solar integration. Small in comparison to the overall needs, but just one of many rapidly improving technologies.

“If investments in the smart grid infrastructure continue, electric vehicles may become ubiquitous — both because of the economic and environmental sense they make for consumers, and because of the vast store of batteries that will be available to grid operators to balance out the intermittency of wind and solar resources.”

“There are several major studies and research showing how the United States could reach 100 percent renewable electricity by 2050. Over the next two decades, the continually rising costs of fossil fuels will make it prohibitive to continue burning them, so we’ll witness the overdue transition to a largely renewable system. Smart grid upgrades will feature two-way communication to consumer appliances, real-time pricing information, more efficient transmission infrastructure, and advanced battery and flywheel technologies to balance the inherent fluctuations of wind and solar resources.”

http://www.mnn.com/earth-matters/energy/blogs/quayle-hodek-a-young-ceo-running-with-the-wind?hpt=Sbin

(2) “What if solar got the same subsidies as coal?” (Oct 21, 2010)
http://cleantechnica.com/2010/10/21/what-if-solar-got-the-same-subsidies-as-coal/

Coal subsidies: The U.S. coal industry enjoyed subsidies of around $17 billion between 2002 and 2008, including tax credits for production of "nonconventional" fuels ($14.1 billion), tax breaks on coal royalties ($986 million), exploration, and development breaks ($342 million), according to a study by the Environmental Law Institute.

http://sierraclub.typepad.com/mrgreen/2010/03/does-the-coal-industry-get-subsidies.html

Solar and wind subsidies: So far, the government has handed out about $5.4 billion, according to the Energy Department.

http://money.cnn.com/2010/11/18/news/economy/renewable_energy_tax_credit/index.htm

(3) Very informative investigative article http://wonkroom.thinkprogress.org/2011/02/03/manchin-coal-subsidies/

(4) “Most long range forecasts of technical feasibility in future time periods dramatically underestimate the power of future technology because they are based on what I call the “intuitive linear” view of technological progress rather than the “historical exponential view.” To express this another way, it is not the case that we will experience a hundred years of progress in the twenty-first century; rather we will witness on the order of twenty thousand years of progress (at today’s rate of progress, that is).” Ray Kurzweil http://www.kurzweilai.net/the-law-of-accelerating-returns

(5) During the past 11 years, as the editor of the leading nanoscale technologies web portal, I read and posted over 50,000 articles about advanced and frequently mind-blowing technologies. I have closely followed the very rapid progress in our understanding and utilization of the unique properties of the nanoscale (which greatly differ from the properties that we already understand). At the very least, we are headed for a future that not one of us can predict; what we can predict is that we will undoubtedly see old myths about technologies shattered and changes beyond our current level of comprehension.

Read More...

Page 17«..10..15161718


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick